|
MRPS31 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
6.10622663543836E-15 |
| Normal-vs-Stage3 |
1.62447832963153E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
1.337210E-01 |
| Stage1-vs-Stage3 |
1.839170E-03 |
| Stage1-vs-Stage4 |
1.85612999999973E-05 |
| Stage2-vs-Stage3 |
1.778450E-03 |
| Stage2-vs-Stage4 |
3.89310000000753E-05 |
| Stage3-vs-Stage4 |
7.285900E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.67994523742254E-12 |
| Normal-vs-Asian |
1.62447832963153E-12 |
| Caucasian-vs-AfricanAmerican |
9.759600E-01 |
| Caucasian-vs-Asian |
7.365600E-01 |
| AfricanAmerican-vs-Asian |
9.131000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
7.639600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
1.47209999745712E-08 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.982200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.044400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.682440E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.162800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.196400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.427800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.04429999999256E-05 |
| Classical-VS-Follicular |
1.67645999999966E-05 |
| Classical-VS-Other |
9.380200E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
7.76759767617818E-11 |
| Tall-VS-Other |
3.882100E-02 |
| Tall-VS-Normal |
1.62436730732907E-12 |
| Follicular-VS-Other |
1.824640E-01 |
| Follicular-VS-Normal |
1.62558855265615E-12 |
| Other-VS-Normal |
1.44059999995783E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62447832963153E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
1.538860E-03 |
|
|
